Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Ask yourself this before buying. How many shares will management pick up at this low price. I've met management and board members during the past 3 annual meetings. The second to last the CEO had no clue what I was doing showing up at the main plant. I explained I was there for the annual meeting. I sensed there something was not right. The first annual meeting i sensed the ceo to be arrogant. Lasf years annual meeting was stocked with employees, and maybe 5 investors. I drilled the ceo about timelines, and failures. The ceo seemed deceptive in his usually soft spoken pretentious voice. I guarantee you they will not pick up any shares at this low price. If they do it will be a token, maybe ten thousand dollars worth, so to continue this false hope. The ceo has been running a deceptive shell game with their pipeline, my opinion.
I've met them. Shifty and untrustworthy. The worse of the worst. Arrogant chisters
Nobody buying horst and his wife's bull----
Redhill hasn't been a partner for quite a while. ??
Right behind you. I own a huge chunk. Too much. Good luck.
Serious question. Do you believe this company will survive. Biggest mistake of my life.
Cannabis film as well with tilray, without fda authorization.
How about their cannabis film coming up with tilray that should bring in some cash
Sublingual Uptake
mouthSublingual products are the preferred method of treatment for many cancer patients who are taking full extract cannabis oil (sometimes referred to as “hemp oil” or Rick Simpson Oil). Direct sublingual application involves placing precisely decarboxylated cannabis under the tongue, allowing the cannabinoids to immediately enter the bloodstream through the vessel-rich tissues within the sublingual cavity.
Before you swallow, cannabis can also enter the blood stream. Under the tongue and within the mouth there are a large number of blood vessels which can absorb cannabinoids. Common examples of these type of medications include dissolvable strips, sublingual sprays, or medicated lozenges or tinctures.
Sublingual delivery is not only a socially acceptable and convenient way to medicate, but intake through the oral mucosal membranes in your mouth is also a very effective way to ingest cannabinoids. This method provides for rapid and effective absorption directly into your systemic circulation because of the increased bioavailability of the cannabinoids.
“Compared to other delivery methods, uptake through blood vessels and micro-capillaries in your mouth is one of the best ways to increase the bioavailability of cannabinoids.”
Bioavailability is a subcategory of absorption in pharmacology that refers to the fraction of an administered dose of unchanged drug that reaches the blood stream. The only way to achieve true 100% bioavailability, by definition, is to administer a drug intravenously.
Compared to other delivery methods, uptake through blood vessels and micro-capillaries in your mouth is one of the best ways to increase the bioavailability of cannabinoids. This “first-pass” of medication, as it’s referred to, allows the medication to avoid having to pass through your liver where it would be broken down making it significantly less beneficial and bioavailable.
Whenever you take any other medications orally – i.e. swallowing pills or eating an edible – a small fraction of that drug is metabolized in the liver before it even reaches systemic circulation (blood stream), thus decreasing the overall bioavailability of the medication.
Additionally, sublingual delivery provides rapid effects similar to smoking without exposing the lungs to heat, tar, or other unwanted collateral effects, including unpleasant smoke smell, smoky taste, dry mouth, throat irritation and caused both by smoke and hot embers that often enter the user’s mouth and lungs during administration. When ignited, a large percentage of the cannabinoids present in the cannabis literally “go up in smoke.”
DMenuView Sections
THE ANTI-ASTHMATIC DRUG MONTELUKAST ALTERS MICROGLIA PHENOTYPE AND SYNUCLEOPATHY, AND RESTORES LEARNING AND MEMORY IN AN ANIMAL MODEL OF LEWY BODY DEMENTIA
Julia Marschallinger1,Email the author Julia Marschallinger, Barbara Altendorfer2, Nadine Pillichshammer2, Garnweidner-Raith Julia2, Edward Rockenstein3, Eliezer Masliah4, Ludwig Aigner1
PlumX Metrics
https://doi.org/10.1016/j.jalz.2017.06.233
© 2017 Published by Elsevier Inc.
Background
Neurodegenerative diseases are associated with increased neuroinflammation. Leukotrienes are small lipid mediators of neuroinflammatory processes, and thus, leukotriene signaling might be a therapeutic target for neurodegenerative disease such as AD, PD, or Lewy body dementia (LBD).
Methods
6-month old PDGF-promoter-alpha-synuclein (PDGF-a-syn) D-line transgenic mice (abbreviated D-line), an animal model for LBD, were treated per oral gavage daily over a period of 42 days with montelukast (10 mg/kg), an approved leukotriene receptor antagonist for the treatment of asthma. Behavioral analyses (Morris Water Maze – learning and memory) of the animals were performed between days 28 and 40. After transcardial perfusion of the mice on day 42, histological analyses of the hippocampus (proliferation, cell survival, neuroinflammation, alpha-synuclein load) were assessed.
Results
We observed elevated levels of 5-LOX protein, the rate limiting enzyme in leukotriene production, in the hippocampus of 6 months old PDGF-promoter-alpha-synuclein (PDGF-a-syn) mice, an animal model for LBD. D-line animals exhibited elevated levels of neuroinflammation, and most importantly, had learning and memory deficits. Treatment of 6 months old D-line mice for 6 weeks with the leukotriene receptor antagonist Montelukast fully restored learning and memory to a level comparable to WT animals without having any adverse effects regardless of the phenotype. Montelukast significantly reduced microglia soma size (a typical morphological surrogate for microglia activation) and reduced the particle size of the phagosomal marker CD68 suggesting either a reduced microglial activity or a restoration of the phagocytic / lysosomal activity, which is otherwise disturbed in microglia of the aged and of the neurodegenerative brain. Moreover, the Montelukast treatment altered the synucleopathy in the D-line mice.
Conclusions
In summary, the leukotriene receptor antagonist Montelukast was highly efficient in restoring cognitive function in an animal model of LBD, most likely but not necessarily limited through its anti-inflammatory action on microglia. This work paves the road for a further development of Montelukast for the treatment neurodegenerative diseases.
View PDF
Terms & Conditions
Privacy Policy
Help & Contact
View Full Site
The content on this site is intended for health professionals.
Advertisements on this site do not constitute a guarantee or endorsement by the journal, Association, or publisher of the quality or value of such product or of the claims made for it by its manufacturer.
Copyright © 2015 Elsevier Inc. All rights reserved.
NEXT ARTICLE
AAV-MEDIATED EXPRESSION OF HUMAN LDLR MARKEDLY REDUCES AMYLOID DEPOSITION IN A MOUSE MODEL OF AMYLOID-ß AMYLOIDOSIS
Go to previous Article Download this Article Share this Article Add Article to Favorites Go to next Article
[
[
Hide Menu
SEARCH
Search
BROWSE
Home
Journal
Featured
MY CONTENT
Favorites
Downloaded
SETTINGS
My Account
Help
About
Full Site
Journal
Alzheimer's & Dementia: The Journal of the Alzheimer's Association
QUICK LINKS
ISSUES
I would like to know what the going concern is. Not clear if they were paid or not. Therefore if paid,no concern. If not paid, what concern?
Can they be less clear on their 8k
New job posting on indeed: https://ca.indeed.com/Cosmetic-Packaging-jobs?vjk=cb8bc02f88901677
They are recruiting they haven't started testing yet pretty soon the testing I figure by the end of November early December so we should get some MIT term results by the summer
Innovative Cannabis Delivery Technologies on the Rise: The Greater Cannabis Company, Inc. (OTC: GCAN), Aphria, Tilray, Aurora and Canopy Growth
GlobeNewswire•November 2, 2018
POINT ROBERTS, Wash. and KELOWNA, British Columbia, Nov. 02, 2018 (GLOBE NEWSWIRE) -- Investorideas.com, a global news source covering leading sectors including marijuana and hemp stocks releases a sector snapshot with a focus on new and innovative delivery systems coming to market.
Through the month of September, larger Canadian cannabis companies including Aphria Inc. (TSX: APH), which commences trading on the NYSE today (NYSE:APHA), have been investing heavily in new cannabis delivery systems. These technologies have the ability to afford consumers a safer alternative to other routes of cannabinoid delivery, many of which have detrimental health effects.
The global trend is in play in the U.S. as well. This past Wednesday, The Greater Cannabis Company, Inc. (OTC: GCAN), a biopharmaceutical company focused on development and commercialization of innovative delivery systems for the Cannabis market, announced “the completion of development and reformulation of its eluting patch (EPP) for cannabinoid use. The EPP has been successfully developed in the past for pharmaceutical and over the counter (OTC) products, as well as for oral health applications. In preparation for commercializing cannabinoid products, the Company completed extensive testing of its new formulations. The cannabinoid transmucosal patch was found to have additional benefits over those previously mentioned, and which can be found on the Company’s website. GCAN’s product allows consumers to absorb cannabinoids through the vascular buccal mucosa (cheek) directly into the bloodstream, and bypass the GI tract. They look like Listerine fresh breath strips, but instead of melting in your mouth right away they have bioadhesive properties that allow the thin films to unobtrusively stick to the inside of your mouth. The cannabinoid actives loaded on the thin films absorb through the very vascular oral cavity and go right into the bloodstream. The unique delivery system also has a mechanism that allows for an initial rapid release of CBD/THC followed by a slow and gradual release of the cannabinoids on subsequent layers of the same thin film. The intent behind the fully dissolvable patch is to offer consumers a needle-free systemic delivery of cannabinoids, while effectively bypassing the digestive and hepatic systems, and without the side effects typically found with smoking or vaping.”
“The Company has entered into a new stage of aggressively ramping up its efforts to commercialize the technology through sublicensing and joint venture agreements. Target partners include licensed producers and dealers in the United States, Canada and abroad, as well as pharmaceutical companies focused on cannabinoids therapies.”
According to the company’s news – “New delivery systems are making their way into the industry. By way of example - the industry is fast adopting similar delivery technologies as seen in recent transactions.”
Standardized and controlled dosing is driving cannabis companies strategic direction, and what may been fueling many of these delivery system transactions. This new and innovative U.S. company (OTC: GCAN) is correct and right on the money in not only seeing the trend, but participating in it.
Aurora Cannabis Inc. (NYSE: ACB) (TSX: ACB.TO) announced it acquired an equity stake in CTT Pharmaceutical Holdings Inc. back in September of this year, converting the $1,000,000 USD/5% debenture into equity shares of CT, giving an approximate 9.14% equity ownership stake in CTT while still holding a warrant which enables Aurora to increase its equity ownership to 42.5%. CTT’s principal asset is a unique and novel patented drug delivery technology, an orally administered, fast-dissolving, thin film (the “Wafer”). This technology platform will target both the human and veterinary (pet) markets for treatment of many diseases. The Company believes that its Wafer technology will be one of the first to gain use in major markets such as pain management. Several Canadian and U.S. patents protect the Oral Thin Film (Wafer) formulation.
From the news, “CTT’s oral fast dissolving drug delivery systems consist of edible Wafers that dissolve without water and within a few seconds after placement in the mouth. The majority of drugs administered using our drug delivery system mirror injections in that they have the ability to enter the bloodstream quickly, are convenient and discrete, and can be administered anywhere. A faster absorption rate is achieved because the mouth contains a very thin mucosa and is extremely vascular. There is no smoke inhalation, less degradation of medication (by bypassing the stomach) and most importantly lower dosage units are required given the efficacy of absorption. Patient compliance is also improved especially with those who have a fear of choking or difficulty swallowing, and/or are pediatric, geriatric or incapacitated.”
Also in September, IntelGenx Corp. announced that it had executed a non-binding letter of intent with Tilray, Inc. (NASDAQ: TLRY) to co-develop and commercialize oral film products infused with recreational and medical cannabis (“cannabis-infused VersaFilm™”), in anticipation of amended cannabis regulations which would allow adult-use consumers to purchase edible products.
“Through the company’s work on VersaFilm with Tilray, IntelGenx Corp has also developed new products out of this technology, specifically RIZAPORT. The company recently announced that its commercialization partner for RIZAPORT® (10mg) in Spain, Groupo Juste, which is now part of Exceltis Healthcare, has received national marketing authorization from the Spanish Agency of Medicines and Medical Devices (AEMPS) for the product.”
“RIZAPORT® is a proprietary oral thin film formulation of rizatriptan for the treatment of acute migraines. RIZAPORT® offers an innovative and potentially advantageous therapeutic alternative for many migraine patients, primarily patients who suffer from dysphagia or migraine-related nausea, due to its convenient dosing, facile intake due to the lack of need for water, and neutral flavor.”
Continuing that same September delivery trend, CURE Pharmaceutical announced that “it entered into a multi-year licensing agreement for the first time with a leading international cannabis company, Canopy Growth (NYSE: CGC) (TSX: WEED.TO). Under the terms of the agreement, the cannabis company will have an exclusive license to CURE’s patented, multi-layer oral thin film (OTF) CUREfilm technology for use with cannabis extracts and biosynthetic cannabinoids in markets around the world.“
“Whole plant extracted, biosynthesized and synthetic cannabinoids all hold therapeutic promise for given indications and intended uses,” said Rob Davidson, CEO and chairman of CURE Pharmaceutical. “At CURE, we focus on synthetic cannabinoids for CUREfilm products, but with our new licensing business model, we will expand the impact and applications of our technology to these other promising approaches by partnering with an industry leader in this market.”
Aphria Inc. (TSX: APH) (NYSE:APHA) was no exception to the move of big cannabis companies buying into cannabis delivery systems. Aphria and Rapid Dose Therapeutics Inc., a Canadian bio-technology company focused on innovative drug delivery solutions, announced as well in September that they have “signed a non-binding Memorandum of Understanding related to RDT's QuickStrip™ products. Under the terms of the MOU, the companies intend to enter into a definitive agreement in the near future pursuant to which RDT will provide Aphria with exclusive global preferred rights to produce, distribute and sell QuickStrip™ products for cannabis markets around the world.”
According to their news, “Aphria is committed to bringing breakthrough innovations to the global cannabis market, which is why we are excited to introduce RDT as a strategic innovation partner,” said Jakob Ripshtein, Chief Commercial Officer at Aphria. “They have developed a truly innovative product that will offer both patients and consumers a new way to consume and experience cannabis. We eagerly anticipate launching QuickStrip™ delivery technology across our portfolio of medical and adult-use brands and look forward to extending this valuable partnership to other markets around the world.”
Seeing the amount of deal flow in the sector, the CEO is ramping up the roll-out for The Greater Cannabis Company, Inc. (OTC: GCAN). The Company’s sole focus now is to bring its licensed technology to market. “The technology has the ability to afford consumers a safer alternative to other routes of cannabinoid delivery, many of which have detrimental health effects. As part of its strategic initiative, the Company is seeking to expand its sales team with the intent to grow deal flow, and accelerate the sales cycle.”
Patience grasshopper
1.99 next week
Keeps on getting better
Nothing wrong with tlry it's just people overpaid because of the few shares available.
I've been invested here for about 5 years definitely not a one-trick pony but cannabis is a very welcome and good surprise
It was only 100 shares and it was also 5 cents below the bid. Just cheap manipulation to distort people's view. It was done seconds before the close.
Looking good
Why would they? Strange question. On the contrary they will soon be starting a study 2A on montelukast for mild case of Alzheimer's as well continuing on the rest of their pipeline look it up
Was personally told by the CEO Horst
Intelgenx looking to move into medical and recreational canabais
THC Strips: Everything You Need To Know About The Newest Cannabis Craze
Cannabis connoisseurs (or cannasseurs, if you will) love their novelty. This love for all things differeAll Postsnt and new heavily translates into the cannabis market. From homemade bongs to moon rock weed to sploofs, vape pens, and concentrates of all sorts, the inventiveness of the developing marijuana industry seems to know no bounds. And just when you think there’s nothing new on the horizon—BAM!—up pops something new that you never knew you needed.
THC Strip on a finger
Source: Dupont.com
Case in point: the THC strip. You may have heard your friends talk about this nifty new cannabinoid delivery system, but what exactly is it? What are they used for? How are they made? And what are their benefits over smoking and eating? The experts at Honest Marijuana are here to answer all those questions. In this article, we’ll go through the science behind this unique method of dating Mary Jane and give you everything you need to know about the next big craze in cannabis.
What Are THC Strips?
THC strips are small squares of edible “paper” that dissolve when they come in contact with water. In the case of THC strips, it’s your saliva that causes the whole thing to dissolve. Have you ever seen or had a breath strip? THC strips are pretty much the same thing only they contain an extra ingredient—THC—to give it more kick.
What Are THC Strips Used For?
THC strips are used as an inconspicuous way to get a dose of THC anytime, anywhere. These type of dissolvable strips are especially useful for those who take THC or CBD for medical reasons. There’s no need to light up and suffer the stigma associated with the tell-tale marijuana smell just to get a bit of pain relief or to take the edge off of post-traumatic stress disorder. THC strips are just one in a long line of cannabis dosing methods that includes, smoking, dabbing, edibles, tinctures, waxes, oils, shatters, and pretty much everything else that you can think of.
How Do You Use THC Strips?
How to consume a THC strip
Source: Tsukioka.company.weiku.com
THC strips work similar to the more-familiar breath strips, only with a slight twist. Instead of placing the breath strip on your tongue and swallowing the dissolved material, you slip the THC strip under your tongue and allow the dissolved material to absorb into your bloodstream through the sublingual artery. An alternative delivery method involves placing the THC strip against the side of your check. This results in a slightly slower on-set with a more mellow, longer-lasting effect.
THC Strips Vs. Other Types Of Edibles
THC strips are consumed through the mouth like other edibles, but this is where the similarity ends. With regular edibles, that you swallow (let’s say a cookie, for example), the cannabis in the mixture is bound to the fat molecules. Your stomach acid has to break everything down before the cannabinoids can be absorbed through either your stomach lining or your intestinal lining. After they’re absorbed, they pass through your liver before entering your bloodstream and being carried to your brain. All of this takes time. This long trip through the digestive system, and through the filter that is your liver, serves to remove some of the potency of the THC ingested. This concept is known as bioavailability. Edibles provide less bioavailability because of the destructive properties of your stomach and liver.
THC strips, on the other hand, provide increased bioavailability because the cannabinoids are absorbed directly into an artery (sublingual) which is only a hop, skip, and a jump from your brain (where the THC takes effect). From the sublingual artery, the unfiltered THC travels to the external carotid artery, to the internal carotid artery, and then to your brain.
The science behind consuming a strip
Source: Silver-Health.co.uk
As you can see, it’s a pretty short trip from under your tongue to inside your brain. That’s the beauty of the THC strip. The sublingual absorption of the THC basically skips the extra step of traveling through the stomach and liver before reaching the bloodstream.THC strips even provide better bioavailability than smoking or dabbing because the cannabinoids don’t have to travel through, and be filtered by, the lungs before reaching your bloodstream.
How Are THC Strips Made?
Each manufacturer will have their own unique method. But to give you an idea of what goes into those dissolvable strips, here’s a basic recipe.
Ingredients:
22.4 grams pullulan
1.0 gram carrageenan
0.15 grams xanthan gum
0.15 grams locust bean gum
0.8 grams sorbitol
71.85 grams water
2.5 grams emulsified mint oil
0.5 grams herb extract (not THC)
0.3 grams aspartame
0.25 grams citric acid
Microencapsulated THC extract (liquid THC)
Directions:
Measure pullulan, carrageenan, xanthan gum, locust bean gum, sorbitol, aspartame, and citric acid into a large mixing bowl.
Mix well.
While stirring, slowly pour water into the bowl.
Continue mixing until you’ve created a gel.
Add emulsified mint oil, herb extract, and THC extract.
Combine ingredients until everything is homogenous.
Cover loosely (doesn’t have to be airtight) and store overnight.
Pour on a baking pan and spread to desired thickness.
Dry in an oven set between 140 degrees Fahrenheit and 175 degrees Fahrenheit until the mixture is dry to the touch (about 3-8% moisture).
Remove the large sheet from the pan, let it cool, and then cut into small strips.
We don’t suggest that you try this at home. For one thing, some of those ingredients are hard to find. For another thing, they can be rather expensive. Then there’s the whole issue of getting everything just right (thickness, dryness, THC content) so as to actually produce a viable product. We never want to discourage you from experimenting with your cannabis products. That’s where most of the new innovations came from. But this process may be beyond the average Mary Joe or Mary Jane in its cost and complexity. We recommend leaving it to professionals. Save yourself a lot of time and a major headache and just buy your strips from your local dispensary.
Don’t believe us? Look at it this way: Do you know what microencapsulated THC extract is? We didn’t think so. Read on for the answer.
What Is Microencapsulation?
The word “microencapsulation” means to put a substance into a microcapsule. In this case, we’re putting THC extract into those microcapsules. The thing about all this is that those microcapsules are tiny little things (invisible to the naked eye) suspended in liquid. When the liquid dries or evaporates, the microcapsules are left behind, in this case, on the dissolvable strip. Before it was used for the likes of breath strips and THC strips, microencapsulation was, and still is, mainly used in the transport, administration, and targeting of therapeutic drugs for cancer treatment and other diseases.
What is an encapsulation matrix
Source: Watson-inc.com
Microencapsulation of THC, and their subsequent inclusion in the dissolvable strip, provides a number of benefits over just adding THC extract into the mix.
Encapsulated THC is protected against degradation (or spoilage) for extended periods of time.
Encapsulation provides a means to control the release rate of THC.
Encapsulated THC makes consumption simple with a variety of ingestion methods available.
In essence, microencapsulation is a way to control the dosage of the strip, makes the strip easy to consume, and helps the THC last longer. All the things you want from THC you can take anywhere.
Can You Get Other Cannabinoids In Strip Form?
cannabis in strip form
Source: Fgxglobalteam.com
While THC strips may be the most popular, you can certainly get dissolvable strips with other combinations of cannabinoids. Manufacturers usually make a variety of strips with indica, hybrid, and sativa strains. These are just a few of the options you have available:
10 mg THC strip (regular)
1:1 ratio of CBD to THC (e.g., 10 mg CBD and 10 mg THC)
2:1 ratio of CBD to THC (e.g., 10 mg CBD and 5 mg THC)
5 mg THC strip (low-dose)
20 mg THC strip (extra strength)
At this point, you may be wondering why would you want the combination of CBD and THC in one strip? Two words: entourage effect. The entourage effect refers to consuming THC in tandem with CBD (and other cannabinoids) to mitigate a lot of the undesirable effects that THC can produce. That means less paranoia, less uncontrollable thoughts, less uncomfortable feelings. All you get is the good stuff.
Should You Try THC Strips?
Yes, you should. It’s the only way you’ll know for sure if this method of delivery is right for you. But before you run out and purchase the first THC strips you can find, talk to the professionals at your local dispensary. When you do find a product you like, start small and start slow. THC consumed through edibles and strips can take longer to act. Sometimes they can take as long as thirty minutes or more before you feel any effects. Until you know what you’re doing, resist the temptation to take another strip in the hopes of making things go faster. This is just a recipe for a bad trip.
Difference Between OTC and Exchange
• Categorized under Finance | Difference Between OTC and Exchange
stock-marketOTC vs Exchange
Many financial markets around the world, such as stock markets, do their trading through exchange. However, forex trading does not operate on an exchange basis, but trades as ‘Over-The-Counter’ markets (OTC). We’ll examine some differences between exchange trading and over-the counter markets in this article.
Differences
In a market that operates with exchange trading, transactions are completed through a centralized source. In other words, one party acts as the mediator connecting buyers and sellers. There is a specified number of traders that will trade on that single centralized system. This situation places great power on the mediator, and this is a key disadvantage to this type of trading. The positive aspect to this is that it allows for better transaction enforcement, and stricter security. The NYSE is a typical example of an exchange traded market. In such a market, products could be standardized, and it could also be guaranteed that goods and products are in compliance with the terms of trade.
On the other hand, over-the counter markets are generally decentralized. Here, there are many mediators who compete to link buyers to sellers. The advantage to this is that it ensures that costs for intermediary services are as low as possible. The obvious downside is that these markets are usually not regulated, and more prone to untrustworthy and fraudulent mediators. Examples of OTC markets include forex trading markets, as well as markets for buying and selling debt. Over-the-counter markets have overtaken exchange markets in terms of volumes traded daily, mainly due to the increase in electronic trading and the rise in alternative investing.
The differences also demonstrate that there is more counter party risk in over-the-counter traded markets than in exchange traded ones, because the ‘exchange’ acts as the regulatory, and is a counter-part to each transaction thus ensuring the delivery of funds or securities.
Also, exchange traded markets have less chances of price manipulation by mediators, since trading is on a centralized system. However, in OTC markets, it will largely be determined by how many dealers are trading in a particular security at a given time.
And since there are fewer clients willing to trade in OTC markets, the result will be less liquidity, whereas exchange traded markets tend to have many participants and clients, thus, there’s a generally higher level of liquidity.
Summary:
In exchange markets, there’s a regulator (exchange) through which transactions are completed, while in OTC markets there is no regulator.
Exchange markets have less chances of price manipulation, while the many competing traders in OTC markets can manipulate prices.
Exchange markets ensure transaction security, while OTC markets are prone to fraud and dishonest traders.
Read more: Difference Between OTC and Exchange | Difference Between http://www.differencebetween.net/business/finance-business-2/difference-between-otc-and-exchange/#ixzz597pI8HAx
Reverse split vote may 8 2018. 1 for 3 or 1 for 8
Another weasel on this board
There seems to be some heavy buying at .83 follow the money
Aegis starts IntelGenx at buy; PT $3
A partnership for Montelukast would be a good stamp of approval
Posted: Wednesday, November 15, 2017 9:45 AM
Joined: 12/12/2011
Posts: 4075
These are important points, Serenoa and larrytherunner. Montelukast/Singulair target a particular g protein-coupled receptor (cysteinyl leukotriene receptor) that is involved in asthma, inflammation, and Alzheimer's disease.
https://www.ncbi.nlm.nih.gov/pubmed/24456746
There are many other g protein-coupled receptors involved in Alzheimer's disease plus in some cases receptor tyrosine kinases. So maybe the question is does Montelukast do more that inhibit one form of g protein-coupled receptor or does it have an additional mechanism of action (as an antioxidant, for instance). If it does then it may provide an effective treatment for many people during the early stages of Alzheimer's disease.
Back to top
baystate
Posted: Friday, December 8, 2017 12:01 PM
Joined: 1/25/2017
Posts: 2
Intelgenx does now have the funds to start Montelukast/dementia study in first quarter of 2018...they trade on stock exchange=IGXT symbol
Back to top
Larrytherunner
Posted: Friday, December 8, 2017 2:30 PM
Joined: 2/26/2016
Posts: 71
Baystate, thanks for the information. I had read in November that Intelgenx had reached an agreement with the Canadian government for clinical trials. I think when the results come out that this drug is the first effective treatment for Alzheimer's, the big pharmaceutical company people are going to be shocked that, with all the billions they spent on new drug research searching for a high priced blockbuster, they were beaten by an inexpensive drug that has been available to the public for more than 15 years.
I have been taking this drug now for more than 22 months and have gone from extreme mental fatigue and occasional confusion to feeling completely normal again. I am thankful that there are investors like you that will give many other people a chance to resume leading a normal life. I hope you get a big return on your investment.
Across the Atlantic, Ludwig Aigner of Paracelsus Medical University in Salzburg, Austria, is taking a different approach to modulating the immune system. He evaluates the approved asthma medication montelukast. This small molecule blocks leukotriene receptors that cause bronchial tubes to constrict. Leukotrienes are inflammatory molecules that white blood cells release during an asthma attack. Because neurons and microglia also express leukotriene receptors, Aigner decided to check if this type of signaling plays a role in brain inflammation. In aged, forgetful rats, six weeks of montelukast treatment shrank microglia, restored the blood-brain barrier, and boosted learning in the Morris water maze to that of young rats. Intriguingly, montelukast also boosted neurogenesis, suggesting some regenerative effects (see Oct 2015 news). Notably, leukotrienes rise during aging, and after stroke or brain damage.
The idea of repurposing montelukast for Alzheimer’s disease is buoyed by its excellent safety record; alas, the tablet formulation poorly enters the bloodstream, with only 63 percent of it becoming bioavailable. Because of this, Aigner and colleagues reformulated the drug in collaboration with IntelGenx Corp., Saint-Laurent, Canada. IntelGenx packaged the drug in a thin film that is placed in the mouth, either against the cheek or under the tongue. The film dissolves, delivering the drug to the bloodstream.
The researchers tested this delivery method in eight healthy volunteers, who took 10 mg montelukast, a common asthma dosage, both in the traditional tablet form and by film. The film resulted in higher absorption, reaching 95 percent in the bloodstream, an increase of 50 percent over the tablet’s bioavailability. This formulation will allow lower dosing, Aigner said in Vienna.?
The drug crossed the blood-brain barrier, an essential feature for treating AD. After three hours, participants had 3.5 ng/ml in their CSF, rising to 4.25 ng/ml by seven hours. This is the pharmacologically active range, Aigner noted. The researchers next plan to do a Phase 2 study in AD patients in Canada, in collaboration with the research organization Consortium of Canadian Centres for Clinical Cognitive Research (C5R). Aigner noted that the oral film represents a new product that can be patented for commercial development.
Montelukast for dementia phase 2B trial starting first quarter Spencer I Rozin case study look up the company yourselves doing the trials. About 70 patients double blind study
It would be nice but I don't think so but I think we get it early next quarter. Better a little late and done properly. Just my opinion.